THE WOODLANDS, Texas, June 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will be presenting clinical data from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010: The 92nd Annual Meeting and Expo, June 19 – 22, 2010 in San Diego, California and the 70th Scientific Sessions of the American Diabetes Association, June 25 – 29, 2010 in Orlando, Florida.
ENDO 2010: The 92nd Annual Meeting and Expo
David Powell, M.D., Lexicon's senior vice president of metabolism research, will give a presentation at ENDO 2010 titled "LX4211, a Dual SGLT1 and SGLT2 Inhibitor, Shows Rapid and Significant Improvement in Glycemic Control over 4 Weeks in Patients with Type 2 Diabetes Mellitus" on Monday, June 21, 2010 at 11:15 a.m. Pacific Time. Joel Freiman, M.D., M.P.H., Lexicon's senior medical director will also present a poster at ENDO 2010 titled "LX4211, a Dual SGLT1 and SGLT2 Inhibitor, Shows Improvements in Cardiovascular Risk Factors over 4 Weeks in Patients with Type 2 Diabetes Mellitus" (poster #P3-511) on Monday, June 21, 2010 from 1:30 – 3:30 p.m. Pacific Time.
Organized by the Endocrine Society, ENDO 2010 features more than 200 scientific sessions covering the full breadth of endocrinology — from basic and translational research to clinical practice. The ENDO 2010 scientific program includes 16 Plenary lectures, 140 Case Management Forum and Meet-the-Professor sessions and 78 Symposia — a total of more than 350 presentations from some of the world's leaders in endocrine research and care. More than 7,500 attendees are expected at this year's conference where 2,500 abstracts will be presented.
70th Scientific Sessions of the American Diabetes Association
At the 70th Scientific Sessions of the American Diabetes Association, Dr. Freiman will present a poster titled "LX4211, a Dual SGLT2/SGLT1 Inhibitor, Shows Rapid and Significant Improvement in Glycemic Control over 28 Days in Patients with Type 2 Diabetes (T2DM)" (poster #17-LB) during the poster session titled "Pharmacologic Treatment of Diabetes or its Complications" on Monday, June 28, 2010 from 12:00 – 2:00 p.m. Eastern Time.
The 70th Scientific Sessions of the American Diabetes Association is the largest meeting providing education and information to all members of the diabetes community, including physicians, scientists, nurses, nurse practitioners, dietitians, pharmacists, podiatrists, psychologists and other health care professionals. More than 15,000 professionals gather each year to share research, treatment recommendations and advances toward a cure for diabetes.
LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes. LX4211 inhibits both sodium-glucose cotransporter type 2, or SGLT2, and sodium-glucose cotransporter type 1, or SGLT1. SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney. SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney. In a combined Phase 1 single ascending-dose and multiple ascending-dose study, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion. In preclinical studies, animals treated with LX4211 demonstrated increased urinary glucose excretion and decreased blood HbA1c levels (a marker of long-term blood sugar levels). Importantly, urinary glucose excretion returned to baseline after treatment was discontinued.
For more information on LX4211, and to access the presentations (available after June 21 and 28, 2010, respectively), please visit www.lexpharma.com.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211 and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.